查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971822

新一代抗體療法市場分析及預測（至2035年）：按類型、產品類型、技術、應用、製程、最終用戶、開發階段、實施類型、功能和模式分類

Next Generation Antibody Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Process, End User, Stage, Deployment, Functionality, Mode
出版日期: | 出版商: Global Insight Services | 英文 336 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計新一代抗體療法市場將從2024年的36億美元成長到2034年的94億美元，複合年成長率約為10.1%。新一代抗體療法市場涵蓋旨在提高疾病治療的特異性、療效和安全性的先進生物製藥，包括雙特異性抗體、抗體藥物複合體和工程化抗體片段。在分子工程創新和精準醫療的推動下，該市場預計將在腫瘤學、免疫學和感染疾病取得重大進展，滿足未被滿足的醫療需求並拓展治療應用。

新一代抗體療法市場正經歷強勁成長，這主要得益於生技和精準醫療的進步。單株抗體因其在多種疾病標靶治療中的有效性而成為市場成長的主要驅動力。具有雙重標靶化能力的雙特異性抗體因其在腫瘤治療方面的潛力而備受關注，並成為第二大成長領域。抗體藥物複合體（ADC）也正在崛起，成為重要的細分市場，它將抗體的特異性與強效細胞毒性藥物結合。腫瘤領域仍然是成長最快的領域，反映出對創新癌症治療方法的迫切需求。自體免疫疾病領域緊隨其後，這主要得益於旨在調節免疫反應的新型抗體療法的開發。抗體設計和生產技術的改進等技術進步正在加速市場成長。對個人化醫療的日益重視正在推動對客製化抗體療法的需求。製藥公司之間的策略聯盟和夥伴關係正在促進創新並拓展治療產品線。監管支持和加速核准流程進一步強化了市場動態，促進了新型抗體療法的上市。

市場區隔
按類型 單株抗體、雙特異性抗體、抗體藥物複合體、抗體片段、多多株抗體
產品 治療性抗體、診斷性抗體、研究性抗體、抗體片段
科技 噬菌體展示、融合瘤、基因轉殖小鼠、細菌展示、酵母展示、哺乳動物細胞展示
應用領域 腫瘤科、自體免疫疾病、感染疾病、心血管疾病、神經系統疾病、代謝性疾病
過程 藥物發現、開發、生產、品管和監管核准
最終用戶 製藥公司、生技公司、研究機構、受託研究機構
步 臨床前研究、臨床試驗與商業化
部署 內部、外包
功能 標靶治療、免疫療法、合併療法
給藥途徑 靜脈注射、皮下注射、肌肉注射和口服給藥

市場概況：

新一代抗體療法市場正經歷著劇烈的變革，創新公司推出的尖端療法佔據了市場佔有率的主導地位。定價策略競爭激烈，反映出市場對更有效、更具標靶性的治療方法的迫切需求。隨著各公司努力滿足未被滿足的醫療需求並提高療效，新產品上市數量迅速成長，市場呈現這樣的特徵。旨在加速產品開發和市場准入的策略聯盟和夥伴關係進一步加劇了這種競爭格局。從競爭標竿分析的角度來看，主要參與者不斷創新以保持其競爭優勢。監管政策對市場產生了重大影響，北美和歐洲的嚴格監管準則影響市場動態。監管環境正在不斷演變，以促進療法開發，並強調透明度和安全性，各公司正在大力投資研發，以有效遵守這些法規。隨著市場的成熟，抗體工程和新型遞送平台的進步有望推動市場顯著成長，並為相關人員帶來豐厚的盈利機會。

主要趨勢和促進因素：

新一代抗體療法市場正經歷強勁成長，這主要得益於生技和個人化醫療的突破性進展。關鍵趨勢包括雙特異性抗體的開發，這種抗體能夠增強標靶化能力和治療效果。抗體藥物複合體（ADC）的興起正在革新癌症治療，它能將細胞毒性藥物直接遞送至癌細胞，並最大限度地減少副作用。此外，為了滿足對標靶治療的需求，用於治療自體免疫疾病的單株抗體也日益受到關注。推動因素包括抗體工程技術的進步和慢性病的日益增加。監管核准的加快為市場擴張創造了有利環境。此外，生物技術公司與研究機構之間的合作正在促進創新並加速開發平臺。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在不斷完善，對先進療法的需求也不斷成長。那些投資於紮實研發和策略夥伴關係的公司將更有能力掌握這些快速成長的機會。

限制與挑戰：

新一代抗體療法市場面臨許多重大限制和挑戰。其中一個主要限制因素是高昂的研發和生產成本，這可能成為中小企業進入市場的壁壘，並限制其市場准入。這種財務壁壘往往導致市場力量集中在少數幾家大型公司手中，扼殺創新。監管障礙也是一項重大挑戰。新療法的嚴格核准流程會延緩市場進入並增加成本。這種法規環境要求進行大規模的臨床試驗。抗體生產的複雜性也是一大挑戰。生產這些療法需要先進的技術和專業知識，並且難以有效率地擴大規模。這種複雜性可能導致產品品質不穩定和供應鏈問題。傳統治療方法的競爭進一步阻礙了市場滲透。許多醫療服務提供者和患者仍然忠於現有治療方法，從而減緩了新型抗體療法的普及。最後，智慧財產權和專利糾紛也會阻礙市場成長。競爭格局中充斥著圍繞專有技術的法律糾紛，這分散了研發資源。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 雙特異性抗體
    • 抗體藥物複合體
    • 抗體片段
    • 多株抗體
  • 市場規模及預測：依產品分類
    • 治療性抗體
    • 診斷抗體
    • 研究抗體
    • 抗體片段
  • 市場規模及預測：依技術分類
    • 噬菌體展示
    • 融合瘤
    • 基因改造小鼠
    • 細菌展示
    • 酵母展示
    • 哺乳動物細胞展示
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 自體免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神經系統疾病
    • 代謝性疾病
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 發展
    • 製造業
    • 品管
    • 監管部門核准
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 合約研究機構
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 臨床試驗
    • 已上市
  • 市場規模及預測：依發展狀況
    • 內部開發
    • 外包
  • 市場規模及預測：依功能分類
    • 標靶治療
    • 免疫療法
    • 加入
  • 市場規模及預測：依管理途徑
    • 靜脈注射
    • 皮下注射
    • 肌肉內注射
    • 口服

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • MacroGenics
  • ImmunoGen
  • MorphoSys
  • Genmab
  • Pieris Pharmaceuticals
  • AbCellera
  • Xencor
  • Adimab
  • MabSpace Biosciences
  • Harbour BioMed
  • Zymeworks
  • Bicycle Therapeutics
  • Crescendo Biologics
  • Mabion
  • I-Mab

第9章：關於我們

簡介目錄
Product Code: GIS34082

Next Generation Antibody Therapeutics Market is anticipated to expand from $3.6 billion in 2024 to $9.4 billion by 2034, growing at a CAGR of approximately 10.1%. The Next Generation Antibody Therapeutics Market encompasses advanced biologic drugs engineered to enhance specificity, efficacy, and safety in treating diseases. This includes bispecific antibodies, antibody-drug conjugates, and engineered antibody fragments. Driven by innovations in molecular engineering and a focus on precision medicine, this market promises significant advancements in oncology, immunology, and infectious diseases, addressing unmet medical needs and expanding therapeutic applications.

The Next Generation Antibody Therapeutics Market is experiencing robust growth, propelled by advancements in biotechnology and precision medicine. Monoclonal antibodies lead the market, driven by their efficacy in targeted therapies for various diseases. Bispecific antibodies, offering dual-targeting capabilities, are the second-highest performing sub-segment, gaining traction for their potential in oncology treatments. Antibody-drug conjugates are also emerging as a critical segment, combining antibody specificity with potent cytotoxic agents. The oncology therapeutic area remains the top-performing segment, reflecting the high demand for innovative cancer treatments. Autoimmune diseases follow, benefiting from the development of novel antibody therapies aimed at modulating immune responses. Technological advancements, such as improved antibody engineering and production techniques, are accelerating market growth. The increasing focus on personalized medicine is driving demand for tailored antibody therapies. Strategic collaborations and partnerships among pharmaceutical companies are fostering innovation and expanding the therapeutic pipeline. Regulatory support and expedited approval processes further enhance market dynamics, facilitating the introduction of novel antibody therapeutics.

Market Segmentation
TypeMonoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Antibody Fragments, Polyclonal Antibodies
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Antibody Fragments
TechnologyPhage Display, Hybridoma, Transgenic Mouse, Bacterial Display, Yeast Display, Mammalian Cell Display
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases
ProcessDiscovery, Development, Manufacturing, Quality Control, Regulatory Approval
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
StagePreclinical, Clinical Trials, Commercialized
DeploymentIn-House, Outsourced
FunctionalityTargeted Therapy, Immunotherapy, Conjugation
ModeIntravenous, Subcutaneous, Intramuscular, Oral

Market Snapshot:

Next Generation Antibody Therapeutics Market is witnessing a dynamic shift, with market share being dominated by innovative companies launching advanced therapeutics. Pricing strategies remain competitive, reflecting the high demand for more effective and targeted treatments. The market is characterized by a surge in new product launches, as companies strive to address unmet medical needs and enhance therapeutic efficacy. This competitive landscape is further invigorated by strategic collaborations and partnerships that aim to accelerate product development and market entry. In terms of competition benchmarking, key players are continuously innovating to maintain their competitive edge. Regulatory influences play a significant role, with stringent guidelines in North America and Europe impacting market dynamics. The regulatory landscape is evolving, encouraging transparency and safety in therapeutic development. Companies are investing heavily in research and development to navigate these regulations effectively. As the market continues to mature, advancements in antibody engineering and novel delivery platforms are expected to drive substantial growth, offering lucrative opportunities for stakeholders.

Geographical Overview:

The Next Generation Antibody Therapeutics Market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, propelled by substantial investments in biotechnology and a strong focus on innovative therapeutic solutions. The presence of major pharmaceutical companies and research institutions further bolsters the region's market dominance. Europe follows closely, with significant government support for biotechnological research and a well-established healthcare infrastructure. The region's emphasis on personalized medicine and advanced therapeutics enhances its market potential. In Asia Pacific, the market is expanding rapidly, driven by increasing healthcare expenditure and a growing focus on precision medicine. Countries like China and India are emerging as key players, with rising investments in biopharmaceutical research and development. Latin America and the Middle East & Africa are burgeoning markets with increasing potential. Brazil and Saudi Arabia are witnessing a surge in biotechnology investments, recognizing the importance of next-generation antibody therapeutics in advancing healthcare outcomes.

Key Trends and Drivers:

The Next Generation Antibody Therapeutics Market is experiencing robust growth driven by breakthroughs in biotechnology and personalized medicine. Key trends include the development of bispecific antibodies, which enhance targeting capabilities and therapeutic efficacy. The rise of antibody-drug conjugates (ADCs) is revolutionizing cancer treatment by delivering cytotoxic agents directly to cancer cells, minimizing collateral damage. The market is also witnessing an increased focus on monoclonal antibodies for autoimmune diseases, reflecting the demand for targeted therapies. Drivers include technological advancements in antibody engineering and a growing prevalence of chronic diseases. Regulatory approvals are accelerating, providing a favorable landscape for market expansion. Moreover, collaborations between biotech firms and research institutions are fostering innovation and expediting the development pipeline. Opportunities abound in emerging markets, where healthcare infrastructure is improving, and demand for advanced therapeutics is rising. Companies investing in robust R&D and strategic partnerships are well-positioned to capitalize on these burgeoning opportunities.

Restraints and Challenges:

The Next Generation Antibody Therapeutics Market is confronted with several significant restraints and challenges. One primary restraint is the high cost of development and production, which can be prohibitive for smaller companies and limit market entry. This financial barrier often results in a concentration of market power among a few large players, stifling innovation. Regulatory hurdles present another formidable challenge. The stringent approval processes for new therapeutics can delay market entry and increase costs. This regulatory environment demands extensive clinical trials, which are both time-consuming and expensive. The complexity of antibody production also poses a challenge. Manufacturing these therapeutics requires advanced technology and expertise, which can be difficult to scale efficiently. This complexity can lead to variability in product quality and supply chain issues. Market penetration is further hindered by competition from traditional therapies. Many healthcare providers and patients remain loyal to established treatments, slowing the adoption of new antibody therapeutics. Lastly, intellectual property and patent disputes can impede market growth. The competitive landscape is fraught with legal battles over proprietary technologies, diverting resources from research and development.

Key Players:

MacroGenics, ImmunoGen, MorphoSys, Genmab, Pieris Pharmaceuticals, AbCellera, Xencor, Adimab, MabSpace Biosciences, Harbour BioMed, Zymeworks, Bicycle Therapeutics, Crescendo Biologics, Mabion, I-Mab

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by Process
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Bispecific Antibodies
    • 4.1.3 Antibody-Drug Conjugates
    • 4.1.4 Antibody Fragments
    • 4.1.5 Polyclonal Antibodies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Antibody Fragments
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Phage Display
    • 4.3.2 Hybridoma
    • 4.3.3 Transgenic Mouse
    • 4.3.4 Bacterial Display
    • 4.3.5 Yeast Display
    • 4.3.6 Mammalian Cell Display
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Autoimmune Diseases
    • 4.4.3 Infectious Diseases
    • 4.4.4 Cardiovascular Diseases
    • 4.4.5 Neurological Diseases
    • 4.4.6 Metabolic Diseases
  • 4.5 Market Size & Forecast by Process (2020-2035)
    • 4.5.1 Discovery
    • 4.5.2 Development
    • 4.5.3 Manufacturing
    • 4.5.4 Quality Control
    • 4.5.5 Regulatory Approval
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Clinical Trials
    • 4.7.3 Commercialized
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-House
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Targeted Therapy
    • 4.9.2 Immunotherapy
    • 4.9.3 Conjugation
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Intravenous
    • 4.10.2 Subcutaneous
    • 4.10.3 Intramuscular
    • 4.10.4 Oral

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 Process
      • 5.2.1.6 End User
      • 5.2.1.7 Stage
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 Process
      • 5.2.2.6 End User
      • 5.2.2.7 Stage
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 Process
      • 5.2.3.6 End User
      • 5.2.3.7 Stage
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 Process
      • 5.3.1.6 End User
      • 5.3.1.7 Stage
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 Process
      • 5.3.2.6 End User
      • 5.3.2.7 Stage
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 Process
      • 5.3.3.6 End User
      • 5.3.3.7 Stage
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 Process
      • 5.4.1.6 End User
      • 5.4.1.7 Stage
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 Process
      • 5.4.2.6 End User
      • 5.4.2.7 Stage
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 Process
      • 5.4.3.6 End User
      • 5.4.3.7 Stage
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 Process
      • 5.4.4.6 End User
      • 5.4.4.7 Stage
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 Process
      • 5.4.5.6 End User
      • 5.4.5.7 Stage
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 Process
      • 5.4.6.6 End User
      • 5.4.6.7 Stage
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 Process
      • 5.4.7.6 End User
      • 5.4.7.7 Stage
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 Process
      • 5.5.1.6 End User
      • 5.5.1.7 Stage
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 Process
      • 5.5.2.6 End User
      • 5.5.2.7 Stage
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 Process
      • 5.5.3.6 End User
      • 5.5.3.7 Stage
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 Process
      • 5.5.4.6 End User
      • 5.5.4.7 Stage
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 Process
      • 5.5.5.6 End User
      • 5.5.5.7 Stage
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 Process
      • 5.5.6.6 End User
      • 5.5.6.7 Stage
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 Process
      • 5.6.1.6 End User
      • 5.6.1.7 Stage
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 Process
      • 5.6.2.6 End User
      • 5.6.2.7 Stage
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 Process
      • 5.6.3.6 End User
      • 5.6.3.7 Stage
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 Process
      • 5.6.4.6 End User
      • 5.6.4.7 Stage
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 Process
      • 5.6.5.6 End User
      • 5.6.5.7 Stage
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 MacroGenics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ImmunoGen
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 MorphoSys
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Genmab
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pieris Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 AbCellera
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Xencor
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adimab
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 MabSpace Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Harbour BioMed
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Zymeworks
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bicycle Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Crescendo Biologics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Mabion
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 I-Mab
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us